206 related articles for article (PubMed ID: 30922580)
1. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
2. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
Zeng L; Zhang Y; Yang N
J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
[No Abstract] [Full Text] [Related]
3. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
4. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
[No Abstract] [Full Text] [Related]
5. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
Fang W; Huang Y; Gan J; Shao YW; Zhang L
J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
[No Abstract] [Full Text] [Related]
6. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
Wang XF; Zhao QT; Chen C
Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
[No Abstract] [Full Text] [Related]
7. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
Yang X; Huang C; Chen R; Zhao J
Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
[No Abstract] [Full Text] [Related]
8. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Ikeuchi T; Tokuyasu H; Ishikawa S
Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
[TBL] [Abstract][Full Text] [Related]
10. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
[No Abstract] [Full Text] [Related]
11. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
12. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
Niogret J; Coudert B; Boidot R
J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
[No Abstract] [Full Text] [Related]
13. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
[No Abstract] [Full Text] [Related]
14. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.
Cai Y; Wang X; Guo Y; Sun C; Xu Y; Qiu S; Ma K
Medicine (Baltimore); 2019 Jan; 98(1):e13890. PubMed ID: 30608413
[TBL] [Abstract][Full Text] [Related]
15. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
[TBL] [Abstract][Full Text] [Related]
16. Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.
Jiang W; Yang N; Zhang Y
J Thorac Oncol; 2018 Jul; 13(7):e124-e126. PubMed ID: 29935852
[No Abstract] [Full Text] [Related]
17. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
18. Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
Yang X; Li Y; Duan Q; Zhang Q; He M
J Thorac Oncol; 2021 Mar; 16(3):e17-e19. PubMed ID: 33641723
[No Abstract] [Full Text] [Related]
19. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
20. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
